Portfolio company
BiPER Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops small molecule drugs targeting the BiP protein to treat gastrointestinal cancers and other pathological conditions in humans.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Iterion Therapeutic
This biopharmaceutical company develops small molecule inhibitors for patients with Wnt-driven cancers, including hepatocellular carcinoma and colorectal cancer.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
MyCural Therapeutics
This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.
Ribon Therapeutics
This biotechnology company develops small molecule inhibitors targeting stress support pathways for patients with cancer and inflammatory diseases.
1200 Pharma
This biotechnology firm develops small molecule therapies and drug intellectual property for the treatment of cancer patients.
Apexian Pharmaceuticals
This company develops oral small molecule drugs targeting specific proteins to treat patients with cancer and inflammatory bowel diseases.
Galera
This biopharmaceutical company develops small-molecule therapies to reduce the side effects of radiotherapy and improve treatment outcomes for patients with advanced breast cancer.
Scorpion Therapeutics
This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.